ATXS – astria therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $26.00 to $28.00. They now have an "outperform" rating on the stock.
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
Form SC 13G/A Astria Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SC 13G/A Astria Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
Form SC 13D/A Astria Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
Form SC 13G/A Astria Therapeutics, Filed by: Fairmount Funds Management LLC
Form SC 13G Astria Therapeutics, Filed by: Vestal Point Capital, LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.